. Author manuscript; available in PMC: 2022 Jul 11.

Published in final edited form as: J Pediatr Gastroenterol Nutr. 2021 Mar 1;72(3):398–403. doi: 10.1097/MPG.0000000000003002

Table 3.

Inflammatory bowel disease medications used in dual-diagnosis subjects who were diagnosed with inflammatory bowel disease first and in subjects with inflammatory bowel disease alone

Medication	Dual IBD first n=32 [n(%)]	IBD n=150 [n(%)]	RR	95% CI
Medication	Dual IBD first n=32 [n(%)]	IBD n=150 [n(%)]	RR	Lower	Upper
5-ASA	23 (72)	117 (78)	0.746	0.361	1.542
Methotrexate	7 (22)	50 (33)	0.589	0.263	1.318
Thiopurine	6 (19)	24 (16)	1.188	0.514	2.748
Anti-TNF	12 (38)	101 (67)	0.314	0.159	0.619
Vedolizumab	1 (3)	11 (7)	0.433	0.062	3.033
Ustekinumab	1 (3)	4 (3)	1.158	0.177	7.571
Tacrolimus	1 (3)	1 (0.01)	3.538	0.690	18.146

IBD medications and weighted relative risk of developing eosinophilic esophagitis. 5-ASA = 5-aminosalicylate, CI = confidence interval, IBD = inflammatory bowel disease, RR = relative risk; TNF = tumor necrosis factor.